Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.58 |
| ▸ | POLQ | O75417 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25629360 | 0.86 | NOTUM (0.58) | NOTUMPOLQTRPV1PYGLHTT | |
| SCHEMBL16166142 | 0.83 | NOTUM (0.56) | NOTUMPOLQTRPV1PYGLHTT | |
| SCHEMBL2435091 | 0.83 | NOTUM (0.56) | NOTUMPOLQTRPV1PYGLHTT | |
| SCHEMBL16353843 | 0.82 | NOTUM (0.54) | NOTUMPOLQTRPV1PYGLHTT | |
| SCHEMBL25733507 | 0.81 | NOTUM (0.56) | NOTUMPOLQTRPV1PYGLHTT | |
| SCHEMBL3884249 | 0.81 | NOTUM (0.56) | NOTUMPOLQTRPV1HTTCHRNB2 | |
| SCHEMBL3576501 | 0.80 | NOTUM (0.51) | NOTUMPOLQTRPV1PYGLHTT | |
| SCHEMBL965251 | 0.80 | NOTUM (0.51) | NOTUMPOLQTRPV1HTTGAA | |
| SCHEMBL27657777 | 0.80 | NOTUM (0.59) | NOTUMPOLQTRPV1PYGLHTT | |
| SCHEMBL16353627 | 0.80 | NOTUM (0.52) | NOTUMPOLQTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | TSUMURA & CO. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1495757-A1 | PHOSPHODIESTERASE IV INHIBITOR CONTAINING PYRIDYLACRYLAMIDE DERIVATIVE | TSUMURA & CO. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6313153-B1 | ADMINISTERING PYRIDYLACRYLAMIDE COMPOUND FOR THERAPY OF NEPHRITIS | TSUMURA & CO. (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1000935-A1 | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-$g(b) INHIBITORS CONTAINING THE SAME | TSUMURA & CO. (JP) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | PDE3B, PDE3A, PDE2A | NOTUM 1974/4885POLQ 1501/4885TRPV1 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.